LION™-Formulated repRNA in Next-Gen repRNA Vaccine Platform Appears Promising

The creation of new vaccination technologies continues to be at the forefront of scientific inquiry as the globe fights numerous infectious illnesses. Recent research on illnesses like COVID-19 has shown promise for mRNA-based vaccines and their use of lipid nanoparticles (LNPs) for delivery.

The widespread biodistribution of LNPs in the body, which occasionally may have unwanted side effects, is a serious worry.

The potential of HDT Bio Corp.’s AMPLIFY vaccination platform, which combines self-replicating RNA (repRNA) with its localizing cationic nanocarrier (LIONTM) formulation, is recently revealed in a peer-reviewed article published in the journal Molecular Therapy.

The preclinical research showed that the delivery of repRNA vaccines using LION technology had a better safety profile and was more effective than the delivery of repRNA vaccines using LNPs.

The study, which used a mouse model, showed that intramuscular delivery of repRNA using LION technology (repRNA/LION) resulted in localized RNA production that was largely in the muscle.

RepRNA/LNP, which was supplied via LNPs, had a wider dispersion throughout the body. The ability of the LION technology to improve vaccination targeting and distribution is demonstrated by the localization of RNA expression in the muscle.

The results of the study also showed that repRNA/LNP induced both local and systemic innate immune/inflammatory responses, but repRNA/LION restricted innate immune activity to the local injection site without inducing a systemic inflammatory response.

This important differential emphasizes the LION formulation’s safety benefits since it reduces the possibility of systemic inflammation while still inducing potent immune responses.

Interestingly, repRNA/LION elicited a similar antibody and T cell response to repRNA/LNP despite the lack of systemic reactogenicity.

This study further supports the safety and efficacy of the LION-formulated repRNA immunization as a vaccine platform by showing that it can generate potent immune responses without the necessity for systemic distribution.

RepRNA/LION was highly effective in inducing robust neutralizing antibody responses to each antigen in a multivalent vaccination formulation. This technology offers great potential for the creation of vaccines that concurrently target a number of pathogens or antigens, improving defense against a range of illnesses.

The study’s co-author and Chief Executive Officer of HDT Bio, Dr. Steve Reed, stressed that the results show the AMPLIFY platform’s transformational potential to support global vaccination efforts while addressing safety problems with many LNP-delivered RNA vaccines.

AMPLIFY is a potential next-generation vaccine technique because of the special qualities of the LION delivery system, which greatly raises the safety, immunogenicity, and effectiveness of RNA vaccines.

With the release of these positive preclinical results, HDT Bio Corp. keeps moving forward with its dedication to creating cutting-edge RNA vaccine technologies to fight cancer and infectious diseases.

The company’s AMPLIFY platform is an important advancement in the continuous search for safer and more efficient vaccination treatments to improve public health around the globe.